ACADIA PHARMACEUTICALS INC · Drugmakers

ACAD

Low riskNext report: In 7 days (est.)

View price ↗

The short version

A profitable company with growing sales. Institutions are adding.

Going well

Sales up 16% in the latest quarter vs a year ago
Profitable, keeps 37% of sales as profit
Sales up 12% last year

Money moves

No insider buying or selling in the last 30 days
Institutions added 2.2% to their holdings in the quarter ending June 2026 (180 bought, 147 sold)
Held by Ray Dalio (Bridgewater)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$19.74+0.1% that day

Company value: $3.4B; Share price times all shares
Price vs profit (P/E): 8.9x; You pay about $9 for each $1 of yearly profit
Price vs sales: 3.0x; Company value is 3.0 times a year of sales
Cash vs value: 11%; Cash as a share of company value

From ACAD's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$308.0M+16% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $1.1B, up 12% from the 12 months before. Over 5 years, sales grew about 19% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of ACAD. Starting points are the company's recent numbers.

Sales growth+12% a yearRecently: +12% a yearProfit margin33%Last 12 months: 33.4%P/E at the end9xToday: 8.9x. Many steady companies trade at 12x to 25xShare count change+2% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$2.0B

Profit in 5 years$662M

Price these guesses point to$31.33+59% vs $19.74 todayAbout +9.7% a year, before dividends

What today's price needs: with a 33% margin and a 9x P/E, sales would have to grow about 2.1% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

4/6Mixed

PassReturn on equity 15%+Earns a lot on the money owners have in the business.39.9%
PassDebt under half of equityNot relying on borrowed money.No debt reported
PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.36.5%
MissProfitable every yearSteady profits, not one good year.2 of 10 years
PassFree cash flow positiveBrings in more cash than it spends to run and grow.$105.1M
MissShare count not growingNot diluting owners. Falling means buybacks.+5.1% in 3 years

Revenue: $1.1B; +11.9% vs prior year
5-year growth: +19.4%/yr; revenue, per year
Total debt: None; 0.00x equity
Current ratio: 3.83x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: gross margin 40%+. A checklist is a starting point for research, not a verdict.